ABSCIENCES (EPA:AB) AB Science: Financial Communication Agenda 2011
Transparency directive : regulatory news
29/11/2010 17:45
Click here to download pdf version
Paris, 29th November 2010, 5:45 pm
Financial Communication Agenda 2011
The indicative agenda of AB Science's financial publications for the fiscal
year 2011 is as follow:
2010 full-year sales 28th February
2010 full-year results presentation 23rd March
2011 first quarter financial information 15th April
General shareholder's meeting 23rd May
2011 half-year sales and results 30th August
2011 third quarter financial information 11th October
The Company's communications are released after market.
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specialising in
research, development and commercialisation of protein kinase inhibitors
(PKIs), a new class of targeted therapy molecules whose action is to modify
signalling pathways within cells. Through these PKIs, the company targets
diseases with high unmet medical needs (cancer, inflammatory diseases and
central nervous system diseases), in both human and veterinary medicines.
Thanks to its extensive research and development capabilities, AB Science has
its own portfolio of molecules including masitinib, which has already been
registered in veterinary medicine in Europe and is being developed in nine
phase 3 studies in human medicine, including three ongoing studies in
pancreatic cancer, gastric intestinal tumors (GIST) and mastocytosis.
Further information is available on AB Science's website: www.ab-science.com
CONTACTS:
Agnès Villeret (Investors & analysts)
Tel: +33 1 53 32 78 95 - agnes.villeret@citigate.fr
Lucie Larguier (press)
Tel: +33 1 53 32 84 75 - lucie.larguier@citigate.fr